Staidson Beijing Biopharma (300204) — Long-term Investment Intensity
Staidson Beijing Biopharma (300204) has a Long-term Investment Intensity of 20.4% as of December 2019. Long-term investments of CN¥380.77 Million represent 20.4% of total assets of CN¥1.86 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check 300204 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Staidson Beijing Biopharma Long-term Investment Intensity (2015–2019)
This chart shows how Staidson Beijing Biopharma's Long-term Investment Intensity has evolved across 5 annual periods from 2015 to 2019. As of December 2019, the intensity stands at 20.4%, reflecting long-term investments of CN¥380.77 Million against total assets of CN¥1.86 Billion CNY. Explore how well can Staidson Beijing Biopharma service its debt to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Staidson Beijing Biopharma (2015–2019)
The table below presents the year-by-year Long-term Investment Intensity for Staidson Beijing Biopharma from 2015 to 2019, covering 5 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see how much is Staidson Beijing Biopharma worth.
| Year | LT Investment Intensity | LT Investments (CNY) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2019 | 20.4% | CN¥380.77 Million | CN¥1.86 Billion | ▼ -8.1 pp |
| 2018 | 28.6% | CN¥792.60 Million | CN¥2.77 Billion | ▲ +12.0 pp |
| 2017 | 16.6% | CN¥435.88 Million | CN¥2.63 Billion | ▲ +10.1 pp |
| 2016 | 6.5% | CN¥152.98 Million | CN¥2.35 Billion | ▲ +6.1 pp |
| 2015 | 0.4% | CN¥8.19 Million | CN¥2.07 Billion | — |